Trials / Completed
CompletedNCT05119413
Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma
Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma: a Double Blind Prospective Randomzed Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Nice · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Kligman's trio remains the gold standard treatment for melasma. It contain hydroquinone which is an effective anti-melanogenic compound but that has poor tolerance and numerous side-effects. Thiamidol has been proven to be at least as effective as hydroquinone and has a very good safety profile. The objective of this study is to compare the Kligman's trio to the same preparation in which hydroquinone is replaced by thiamidol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | New trio de Kligman | Once daily application in addition to the same sunscreen |
| DRUG | Trio Kligman | Once daily application in addition to the same sunscreen |
Timeline
- Start date
- 2021-11-30
- Primary completion
- 2022-09-16
- Completion
- 2022-12-15
- First posted
- 2021-11-15
- Last updated
- 2026-03-24
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05119413. Inclusion in this directory is not an endorsement.